Fractyl Health's Revita Procedure Shows Promise in Sustained Weight Maintenance After GLP-1 Therapy Discontinuation.

Fractyl Health reported positive 6-month results from its REVEAL-1 open-label study, showing sustained weight maintenance after a single Revita procedure in individuals with obesity who discontinued GLP-1 therapy. The average ablation length was approximately 16 cm, consistent with European real-world experience and ongoing REMAIN-1 Pivotal study. Revita has FDA Breakthrough Device designation for post-GLP-1 weight maintenance.